<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7139252/results/search/disease/results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
  <result pre="a significant amount of the world's population will contract SARS-CoV-II" exact="infection" post="with the current spreading. While a specific treatment is"/>
  <result pre="Herbs Antiviral medication 1 Introduction In December 2019, several unidentified" exact="pneumonia" post="cases occurred in Wuhan, China. On 30 January 2020,"/>
  <result pre="[2], [3]]. The WHO suggested the official name for the" exact="disease" post="from this virus as the coronavirus disease 2019 (COVID-19)."/>
  <result pre="official name for the disease from this virus as the" exact="coronavirus disease" post="2019 (COVID-19). The Coronaviridae Study Group of the International"/>
  <result pre="name for the disease from this virus as the coronavirus" exact="disease" post="2019 (COVID-19). The Coronaviridae Study Group of the International"/>
  <result pre="of Viruses proposed the name of the virus as ‘severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-II)’, designated by its phylogeny"/>
  <result pre="Viruses proposed the name of the virus as ‘severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-II)’, designated by its phylogeny and"/>
  <result pre="proposed the name of the virus as ‘severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-II)’, designated by its phylogeny and taxonomy"/>
  <result pre="and 59,201 deaths worldwide [5]. COVID-19 is the third-known zoonotic" exact="disease" post="from coronavirus after severe acute respiratory syndrome (SARS) and"/>
  <result pre="COVID-19 is the third-known zoonotic disease from coronavirus after severe" exact="acute" post="respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)"/>
  <result pre="is the third-known zoonotic disease from coronavirus after severe acute" exact="respiratory" post="syndrome (SARS) and Middle East respiratory syndrome (MERS) [6]."/>
  <result pre="the third-known zoonotic disease from coronavirus after severe acute respiratory" exact="syndrome" post="(SARS) and Middle East respiratory syndrome (MERS) [6]. SARS-CoV-II"/>
  <result pre="coronavirus after severe acute respiratory syndrome (SARS) and Middle East" exact="respiratory" post="syndrome (MERS) [6]. SARS-CoV-II belongs to the family of"/>
  <result pre="after severe acute respiratory syndrome (SARS) and Middle East respiratory" exact="syndrome" post="(MERS) [6]. SARS-CoV-II belongs to the family of coronaviridae"/>
  <result pre="the mortality rate from COVID-19 at 2–5%, which is substantially" exact="lower" post="than the mortality rate of 10% and 40% in"/>
  <result pre="MERS-CoV at 2–5 and less than 1, respectively [11,12]. The" exact="viral" post="genome analysis suggested that the SARS-CoV-II was a recombinant"/>
  <result pre="samples from the seafood industry and the seafood markets. The" exact="respiratory" post="droplets from coughing or sneezing are the primary mediums"/>
  <result pre="markets. The respiratory droplets from coughing or sneezing are the" exact="primary" post="mediums for human-to-human transmission [17]. The frequent symptoms of"/>
  <result pre="primary mediums for human-to-human transmission [17]. The frequent symptoms of" exact="respiratory" post="illnesses, i.e., a fever higher than 38.1 °C (98%"/>
  <result pre="the majority of patients (80.9%) were considered to have mild" exact="pneumonia" post="or being asymptomatic, which posed big challenges for the"/>
  <result pre="of COVID-19 cases in China suggested the possibility of indirect" exact="viral" post="transmission without a history of close physical connection to"/>
  <result pre="history of close physical connection to the infected individuals. The" exact="viral" post="transfer is possible through the common contaminated objects, viral"/>
  <result pre="The viral transfer is possible through the common contaminated objects," exact="viral" post="aerosolization in confined space, or from the asymptomatic viral"/>
  <result pre="objects, viral aerosolization in confined space, or from the asymptomatic" exact="viral" post="carriers [21]. The general preventive guidelines include frequent hand"/>
  <result pre="and cooking. Social distancing helps to avoid close contact with" exact="symptomatic" post="and asymptomatic individuals [17]. Rapid identification, isolation, and treatment"/>
  <result pre="for COVID-19, most of the case management is supportive and" exact="symptomatic" post="measures. With global pandemic spreading, most of us may"/>
  <result pre="global pandemic spreading, most of us may get the SARS-CoV-II" exact="infection" post="at a certain period. Therefore, individual actions that minimize"/>
  <result pre="at a certain period. Therefore, individual actions that minimize the" exact="infection" post="risk and modulate the severity of the clinical courses"/>
  <result pre="individual risk management strategies to reduce the risk of SARS-CoV-II" exact="infection" post="and moderate the severity of COVID-19. 2 Personal hygiene"/>
  <result pre="hygiene and social distancing determine the individual risk of SARS-CoV-II" exact="infection" post="While the SARS-CoV-II remains viable in the aerosols for"/>
  <result pre="mouth touching reduces the introduction of contaminated hands to the" exact="respiratory" post="mucosal surfaces [25]. Social distancing prevents contact with the"/>
  <result pre="inappropriate use and disposal of the mask may increase their" exact="infection" post="risks. Hence, there is a recommendation to use a"/>
  <result pre="[26]. With the spreading of SARS-CoV-II, one can reduce their" exact="viral" post="contracting risk through these preventive measures. 3 The host"/>
  <result pre="cigarette smoking, determine the clinical severity of COVID-19 [28,29]. 3.1" exact="Chronic" post="disease A new study is refining our knowledge of"/>
  <result pre="smoking, determine the clinical severity of COVID-19 [28,29]. 3.1 Chronic" exact="disease" post="A new study is refining our knowledge of the"/>
  <result pre="of the most severe cases [30,31]. Moreover, the comorbidities of" exact="coronary heart disease" post="(5·8%), and cerebrovascular disease (2·3%) have been reported in"/>
  <result pre="the most severe cases [30,31]. Moreover, the comorbidities of coronary" exact="heart" post="disease (5·8%), and cerebrovascular disease (2·3%) have been reported"/>
  <result pre="most severe cases [30,31]. Moreover, the comorbidities of coronary heart" exact="disease" post="(5·8%), and cerebrovascular disease (2·3%) have been reported in"/>
  <result pre="[30,31]. Moreover, the comorbidities of coronary heart disease (5·8%), and" exact="cerebrovascular disease" post="(2·3%) have been reported in severe cases [32]. Bad"/>
  <result pre="Moreover, the comorbidities of coronary heart disease (5·8%), and cerebrovascular" exact="disease" post="(2·3%) have been reported in severe cases [32]. Bad"/>
  <result pre="tobacco (compared to 11.8% of less severe cases) [33]. Co-existing" exact="metabolic diseases" post="include type 2 diabetes, hypertension, heart disease, a history"/>
  <result pre="11.8% of less severe cases) [33]. Co-existing metabolic diseases include" exact="type 2" post="diabetes, hypertension, heart disease, a history of stroke, and"/>
  <result pre="cases) [33]. Co-existing metabolic diseases include type 2 diabetes, hypertension," exact="heart" post="disease, a history of stroke, and cancers. Therefore, the"/>
  <result pre="and sex The elderly are more prone to infection, including" exact="respiratory" post="diseases than young people, while accompanied by the increased"/>
  <result pre="rate. These age-related immunologic changes are probably the results of" exact="primary" post="or secondary structural and functional changes of bone marrow,"/>
  <result pre="age-related immunologic changes are probably the results of primary or" exact="secondary" post="structural and functional changes of bone marrow, thymus, lymphoid"/>
  <result pre="the epigenomic signature of declining naïve T cells and increasing" exact="monocyte" post="and cytotoxic cell functions were higher in male than"/>
  <result pre="monocyte and cytotoxic cell functions were higher in male than" exact="female" post="elders [35]. The age-related immunologic changes and sex differences"/>
  <result pre="age of sixty-five. The older man is more prone to" exact="infectious diseases" post="with high pro-inflammatory immune responses and low adaptive immune"/>
  <result pre="immunity in the elders [37]. The clinical or subclinical micronutrient" exact="deficiency" post="is common in older adults, which contributes to several"/>
  <result pre="the immune system and promotes the host well-being [40,41]. The" exact="respiratory" post="tract microbiota also influences the host immune responses to"/>
  <result pre="responses to the virus [42]. While the immune responses to" exact="viral infection" post="determine the efficacy of a vaccine, the disrupted gut"/>
  <result pre="to the virus [42]. While the immune responses to viral" exact="infection" post="determine the efficacy of a vaccine, the disrupted gut"/>
  <result pre="contribute to vaccine failures and other inflammatory conditions [43]. The" exact="acute" post="respiratory viral infections disrupt the host-microbiota interactions and create"/>
  <result pre="to vaccine failures and other inflammatory conditions [43]. The acute" exact="respiratory" post="viral infections disrupt the host-microbiota interactions and create the"/>
  <result pre="vaccine failures and other inflammatory conditions [43]. The acute respiratory" exact="viral" post="infections disrupt the host-microbiota interactions and create the intestinal"/>
  <result pre="failures and other inflammatory conditions [43]. The acute respiratory viral" exact="infections" post="disrupt the host-microbiota interactions and create the intestinal dysbiosis"/>
  <result pre="intestinal dysbiosis with the post-viral immune responses, that contribute to" exact="pneumonia" post="development by the secondary bacterial infection [44]. The healthy,"/>
  <result pre="post-viral immune responses, that contribute to pneumonia development by the" exact="secondary" post="bacterial infection [44]. The healthy, diverse intestinal and respiratory"/>
  <result pre="immune responses, that contribute to pneumonia development by the secondary" exact="bacterial infection" post="[44]. The healthy, diverse intestinal and respiratory tract microbiota"/>
  <result pre="responses, that contribute to pneumonia development by the secondary bacterial" exact="infection" post="[44]. The healthy, diverse intestinal and respiratory tract microbiota"/>
  <result pre="the secondary bacterial infection [44]. The healthy, diverse intestinal and" exact="respiratory" post="tract microbiota is then another critical determinant for the"/>
  <result pre="Interferons (IFNs) are the first line of immune defense against" exact="viral infection," post="particularly the type I IFNs and the type III"/>
  <result pre="first line of immune defense against viral infection, particularly the" exact="type I" post="IFNs and the type III IFNs, or IFN-λs [46]."/>
  <result pre="against viral infection, particularly the type I IFNs and the" exact="type III" post="IFNs, or IFN-λs [46]. Despite the preliminary understanding of"/>
  <result pre="roles, IFN-λs are probably the critical antiviral cytokines in the" exact="respiratory" post="epithelial surfaces during the early stages of viral infection."/>
  <result pre="IFN-λs are probably the critical antiviral cytokines in the respiratory" exact="epithelial" post="surfaces during the early stages of viral infection. While"/>
  <result pre="in the respiratory epithelial surfaces during the early stages of" exact="viral infection." post="While the type I IFN signaling during acute viral"/>
  <result pre="surfaces during the early stages of viral infection. While the" exact="type I" post="IFN signaling during acute viral infection increase the pro-inflammatory"/>
  <result pre="of viral infection. While the type I IFN signaling during" exact="acute" post="viral infection increase the pro-inflammatory responses, their signaling in"/>
  <result pre="viral infection. While the type I IFN signaling during acute" exact="viral infection" post="increase the pro-inflammatory responses, their signaling in the persistent"/>
  <result pre="infection. While the type I IFN signaling during acute viral" exact="infection" post="increase the pro-inflammatory responses, their signaling in the persistent"/>
  <result pre="infection increase the pro-inflammatory responses, their signaling in the persistent" exact="infection" post="modulates the counter-regulatory immune responses [47,48]. Some gut microbiomes"/>
  <result pre="responses [47,48]. Some gut microbiomes mediate the IFN responses to" exact="viral infection" post="through their metabolites, such as the Clostridium orbiscindens-derived desaminotyrosine"/>
  <result pre="[47,48]. Some gut microbiomes mediate the IFN responses to viral" exact="infection" post="through their metabolites, such as the Clostridium orbiscindens-derived desaminotyrosine"/>
  <result pre="of Lactobacillus also influence the IFN responses following the influenza" exact="infection" post="[50]. Host dietary pattern is the pivotal determinant of"/>
  <result pre="susceptible individuals for COVID-19 might alleviate their risk of severe" exact="infection" post="[54]. Despite the inconclusive pieces of evidence, oral probiotics"/>
  <result pre="are expecting to be the rational adjunctive option in various" exact="viral" post="disease management [[55], [56], [57]]. 4 The host macro-"/>
  <result pre="expecting to be the rational adjunctive option in various viral" exact="disease" post="management [[55], [56], [57]]. 4 The host macro- and"/>
  <result pre="protective role of vitamin D supplementation for the prevention of" exact="acute" post="respiratory tract infection [[62], [63], [64], [65]]. The effective"/>
  <result pre="role of vitamin D supplementation for the prevention of acute" exact="respiratory" post="tract infection [[62], [63], [64], [65]]. The effective supplementation"/>
  <result pre="vitamin D supplementation for the prevention of acute respiratory tract" exact="infection" post="[[62], [63], [64], [65]]. The effective supplementation needs to"/>
  <result pre="The effective supplementation needs to start before the onset of" exact="respiratory" post="tract infection. However, there is inconclusive evidence regarding the"/>
  <result pre="is inconclusive evidence regarding the underlying mechanisms of vitamin D" exact="deficiency" post="and viral disease development [66]. The potential mechanisms include"/>
  <result pre="evidence regarding the underlying mechanisms of vitamin D deficiency and" exact="viral" post="disease development [66]. The potential mechanisms include the antiviral"/>
  <result pre="regarding the underlying mechanisms of vitamin D deficiency and viral" exact="disease" post="development [66]. The potential mechanisms include the antiviral immune"/>
  <result pre="and genetic or epigenetic regulation [66]. Furthermore, the risk of" exact="viral" post="infections can be reduced by vitamin D. The related"/>
  <result pre="genetic or epigenetic regulation [66]. Furthermore, the risk of viral" exact="infections" post="can be reduced by vitamin D. The related mechanisms"/>
  <result pre="well as decreasing concentrations of pro-inflammatory cytokines that induce inflammation-related" exact="pneumonia" post="[67]. Supportive data for the effective role of vitamin"/>
  <result pre="of COVID-19 could be highlighted by increased case-fatality rates with" exact="chronic" post="disease comorbidity and age, in which lower concentrations of"/>
  <result pre="COVID-19 could be highlighted by increased case-fatality rates with chronic" exact="disease" post="comorbidity and age, in which lower concentrations of 25(OH)D"/>
  <result pre="case-fatality rates with chronic disease comorbidity and age, in which" exact="lower" post="concentrations of 25(OH)D have been reported. Vitamin D deficiency"/>
  <result pre="which lower concentrations of 25(OH)D have been reported. Vitamin D" exact="deficiency" post="is globally prevalent, particularly in the elders [68]. Over"/>
  <result pre="and nursing home residents in the U.S. had vitamin D" exact="deficiency" post="[69,70]. This high prevalence probably contributes to the first"/>
  <result pre="the supplementation benefit in healthy individuals for the prevention of" exact="acute" post="viral respiratory infection [76]. However, vitamin A deficient people"/>
  <result pre="supplementation benefit in healthy individuals for the prevention of acute" exact="viral" post="respiratory infection [76]. However, vitamin A deficient people are"/>
  <result pre="benefit in healthy individuals for the prevention of acute viral" exact="respiratory" post="infection [76]. However, vitamin A deficient people are prone"/>
  <result pre="in healthy individuals for the prevention of acute viral respiratory" exact="infection" post="[76]. However, vitamin A deficient people are prone to"/>
  <result pre="risk, the high severity, and the impaired immune responses to" exact="viral" post="infections, including the respiratory syncytial virus, measle virus, and"/>
  <result pre="and the impaired immune responses to viral infections, including the" exact="respiratory" post="syncytial virus, measle virus, and the influenza virus [77,78]."/>
  <result pre="monocytes or macrophages, T cells, and B cells [79,80]. 4.3" exact="Vitamin C" post="Vitamin C deficiency is associated with pneumonia in several"/>
  <result pre="macrophages, T cells, and B cells [79,80]. 4.3 Vitamin C" exact="Vitamin C deficiency" post="is associated with pneumonia in several pieces of literature"/>
  <result pre="cells, and B cells [79,80]. 4.3 Vitamin C Vitamin C" exact="deficiency" post="is associated with pneumonia in several pieces of literature"/>
  <result pre="[79,80]. 4.3 Vitamin C Vitamin C deficiency is associated with" exact="pneumonia" post="in several pieces of literature in the early days"/>
  <result pre="literature in the early days [81,82]. The immune-modulating effects in" exact="respiratory" post="infection of vitamin C are also well-documented [[83], [84],"/>
  <result pre="in the early days [81,82]. The immune-modulating effects in respiratory" exact="infection" post="of vitamin C are also well-documented [[83], [84], [85],"/>
  <result pre="of vitamin C supplementation in the prevention and treatment of" exact="acute" post="respiratory diseases are inconclusive [[87], [88], [89], [90]]. In"/>
  <result pre="vitamin C supplementation in the prevention and treatment of acute" exact="respiratory" post="diseases are inconclusive [[87], [88], [89], [90]]. In alignment"/>
  <result pre="[87,88]. Moreover, it has been reported that megadoses administration of" exact="Vitamin C" post="before or after the appearance of flu symptoms could"/>
  <result pre="episodes, it has been revealed that the regular supplementation of" exact="Vitamin C" post="had a modest but consistent effect in decreasing the"/>
  <result pre="the risk of common cold without any adverse effects [93]." exact="Vitamin C" post="supplementation is thus the sensible option to prevent and"/>
  <result pre="reductases, selenium has a critical role in the defense against" exact="viral infection" post="through its antioxidant, redox signaling, and redox homeostatic contributions"/>
  <result pre="selenium has a critical role in the defense against viral" exact="infection" post="through its antioxidant, redox signaling, and redox homeostatic contributions"/>
  <result pre="its antioxidant, redox signaling, and redox homeostatic contributions [94]. Selenium" exact="deficiency" post="is associated with increased pathogenicity of several virus infections"/>
  <result pre="Selenium deficiency is associated with increased pathogenicity of several virus" exact="infections" post="[[95], [96], [97]]. In the deficient state, the selenium"/>
  <result pre="selenium supplementation is helpful for the prevention and treatment of" exact="viral" post="infections [[97], [98], [99], [100]]. Recently, it has been"/>
  <result pre="supplementation is helpful for the prevention and treatment of viral" exact="infections" post="[[97], [98], [99], [100]]. Recently, it has been reported"/>
  <result pre="of influenza virus, also shows increased virulence in selenium-deficient mice." exact="Increased" post="virulence is related to several modifications in the viral"/>
  <result pre="mice. Increased virulence is related to several modifications in the" exact="viral" post="genome [95,101]. Furthermore, the immune response, such as proinflammatory"/>
  <result pre="Moreover, the mRNA expression of macrophage inflammatory protein-1α and -1β," exact="monocyte" post="chemotactic protein-1, and RANTES (regulated upon activation, normal T"/>
  <result pre="and related mechanisms, revealing an effective role of selenium-supplementation in" exact="viral" post="diseases. 4.5 Zinc Zinc is an essential micronutrient with"/>
  <result pre="structural component of around 750 zinc-finger transcription factors [102]. The" exact="deficiency" post="of zinc also modifies the development of acquired immunity"/>
  <result pre="[102]. The deficiency of zinc also modifies the development of" exact="acquired" post="immunity by limiting both the certain and outgrowth functions"/>
  <result pre="The function of macrophage also is adversely affected by the" exact="deficiency" post="of zinc through the dysregulation of cytokine production, intracellular"/>
  <result pre="dysregulation of cytokine production, intracellular killing, and phagocytosis [103]. Zinc" exact="deficiency" post="is surprisingly common in modern-day lifestyle [104]. Zinc deficiency"/>
  <result pre="Zinc deficiency is surprisingly common in modern-day lifestyle [104]. Zinc" exact="deficiency" post="impairs the antiviral immunity, particularly to herpes simplex, common"/>
  <result pre="lifestyle [104]. Zinc deficiency impairs the antiviral immunity, particularly to" exact="herpes" post="simplex, common cold, herpes simplex virus, hepatitis C, and"/>
  <result pre="impairs the antiviral immunity, particularly to herpes simplex, common cold," exact="herpes" post="simplex virus, hepatitis C, and the human immunodeficiency virus"/>
  <result pre="immunity, particularly to herpes simplex, common cold, herpes simplex virus," exact="hepatitis" post="C, and the human immunodeficiency virus (HIV) [104,105]. A"/>
  <result pre="common cold, herpes simplex virus, hepatitis C, and the human" exact="immunodeficiency" post="virus (HIV) [104,105]. A meta-analysis of oral zinc supplementation"/>
  <result pre="on the shortened of symptoms and duration of common cold" exact="infection" post="[[106], [107], [108]]. Zinc supplementation was also helpful against"/>
  <result pre="infection [[106], [107], [108]]. Zinc supplementation was also helpful against" exact="hepatitis" post="C virus infection through the induction of metallothionein expressions"/>
  <result pre="[107], [108]]. Zinc supplementation was also helpful against hepatitis C" exact="virus infection" post="through the induction of metallothionein expressions [109,110]. Moreover, research"/>
  <result pre="[108]]. Zinc supplementation was also helpful against hepatitis C virus" exact="infection" post="through the induction of metallothionein expressions [109,110]. Moreover, research"/>
  <result pre="zinc has antiviral effects; it improves immune responses and suppresses" exact="viral" post="replication. Therefore, the consumption of up to 50 mg"/>
  <result pre="it improves immune responses and suppresses viral replication. Therefore, the" exact="consumption" post="of up to 50 mg zinc per day may"/>
  <result pre="the COVID-19 pandemic, likely by improving the host's resistance against" exact="viral infection" post="[102]. However, these studies did not account for the"/>
  <result pre="COVID-19 pandemic, likely by improving the host's resistance against viral" exact="infection" post="[102]. However, these studies did not account for the"/>
  <result pre="components of the SARS-CoV-II lifecycle. These molecular targets include the" exact="viral" post="entry into the host cells, the viral RNA synthesis,"/>
  <result pre="targets include the viral entry into the host cells, the" exact="viral" post="RNA synthesis, and the viral replication [112]. There are"/>
  <result pre="into the host cells, the viral RNA synthesis, and the" exact="viral" post="replication [112]. There are high sequence similarities in the"/>
  <result pre="entry into the host cells 5.2.1 Chloroquine and hydroxychloroquine These" exact="viral" post="entry blockages include chloroquine, hydroxychloroquine umifenovir, and interferon [112]."/>
  <result pre="that chloroquine significantly decreased the human coronavirus-229E replication at a" exact="lower" post="concentration than the clinical dosage [113]. A systematic review"/>
  <result pre="[112]. A non-randomized clinical trial reported the reduction of the" exact="viral" post="load from the hydroxychloroquine-azithromycin combination in twenty COVID-19 patients"/>
  <result pre="trials in the treatment of COVID-19. 5.3 The inhibitors of" exact="viral" post="RNA synthesis 5.3.1 Remdesivir The medications that inhibit viral"/>
  <result pre="of viral RNA synthesis 5.3.1 Remdesivir The medications that inhibit" exact="viral" post="RNA synthesis include remdesivir, favipiravir, and ribavirin. Remdesivir is"/>
  <result pre="the single-stranded RNA viruses, including the Ebola virus, Marburg virus," exact="respiratory" post="syncytial virus, Junin virus, Lassa fever virus, Nipah virus,"/>
  <result pre="the Ebola virus, Marburg virus, respiratory syncytial virus, Junin virus," exact="Lassa fever" post="virus, Nipah virus, Hendra virus, and the coronaviruses [[121],"/>
  <result pre="inhibits the RNA-dependent RNA polymerase, which crucially replicates copies of" exact="viral" post="RNA in the host cells. The animal models and"/>
  <result pre="studies suggested the effectiveness of remdesivir to selectively inhibit the" exact="infection" post="and pathology of MERS-CoV and SARS-CoV-II [125,126]. While the"/>
  <result pre="with the broad-spectrum antiviral activities through its selective inhibition of" exact="viral" post="RNA-dependent RNA polymerase [130]. Favilavir has efficacy against various"/>
  <result pre="Favilavir has efficacy against various RNA viruses, including influenza, ebola," exact="yellow fever," post="chikungunya, norovirus, and enterovirus [131,132]. A recent cell line"/>
  <result pre="on the clinical trials for COVID-19 treatment by the National" exact="Infectious" post="Diseases Scientific Science Research Center and the Shenzhen Third"/>
  <result pre="the clinical trials for COVID-19 treatment by the National Infectious" exact="Diseases" post="Scientific Science Research Center and the Shenzhen Third People's"/>
  <result pre="lopinavir/ritonavir combination without the significant adverse reactions [135,136]. 5.4 The" exact="viral" post="replication inhibitors 5.4.1 The lopinavir-ritonavir combination The medications that"/>
  <result pre="is a fixed-dose medication for the prevention and treatment of" exact="HIV infection" post="[137]. The cytochrome P450 inhibitory effects of ritonavir prolonged"/>
  <result pre="a fixed-dose medication for the prevention and treatment of HIV" exact="infection" post="[137]. The cytochrome P450 inhibitory effects of ritonavir prolonged"/>
  <result pre="inhibitors, such as ritonavir or cobicistat, for the treatment of" exact="HIV infection" post="[143]. The in-vitro studies suggested the inhibitory action of"/>
  <result pre="such as ritonavir or cobicistat, for the treatment of HIV" exact="infection" post="[143]. The in-vitro studies suggested the inhibitory action of"/>
  <result pre="There was the in-vitro evidence of inhibitory action on the" exact="viral" post="replication of viperin among a broad spectrum of DNA"/>
  <result pre="among a broad spectrum of DNA and RNA viruses, including" exact="herpes" post="viruses, West Nile virus, dengue virus, sindbis virus, influenza"/>
  <result pre="flavonoids. The in-vitro studies demonstrated that various flavonoids suppress the" exact="hepatitis" post="C virus, MERS-CoV, and SARS-CoV, through their 3CLpro inhibitory"/>
  <result pre="a long history of this passive antibody treatment in various" exact="infective" post="diseases beyond the era of antimicrobial development [160,161]. A"/>
  <result pre="convalescent plasma from the patients who have recovered from the" exact="viral infection" post="is thus another rational option for COVID-19 management [160,161]."/>
  <result pre="plasma from the patients who have recovered from the viral" exact="infection" post="is thus another rational option for COVID-19 management [160,161]."/>
  <result pre="Study Group of the International Committee on Taxonomy ofThe species" exact="Severe" post="acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it"/>
  <result pre="Group of the International Committee on Taxonomy ofThe species Severe" exact="acute" post="respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat."/>
  <result pre="of the International Committee on Taxonomy ofThe species Severe acute" exact="respiratory" post="syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat. Microbiol.202010.1038/s41564-020-0695-z(Epub"/>
  <result pre="conserved protein domainsVirus Evol.42018vey03510.1093/ve/vey03530568804 8ZhuN.ZhangD.WangW.LiX.YangB.SongJ.ZhaoX.HuangB.ShiW.LuR.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N. Engl. J. Med.382202072773310.1056/NEJMoa200101731978945 9ChenY.LiuQ.GuoD.Emerging coronaviruses: genome"/>
  <result pre="18AdhikariS.P.MengS.WuY.-J.MaoY.-P.YeR.-X.WangQ.-Z.SunC.SylviaS.RozelleS.RaatH.Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of" exact="coronavirus disease" post="(COVID-19) during the early outbreak period: a scoping reviewInfect."/>
  <result pre="causes, clinical manifestation and diagnosis, prevention and control of coronavirus" exact="disease" post="(COVID-19) during the early outbreak period: a scoping reviewInfect."/>
  <result pre="19ChenN.ZhouM.DongX.QuJ.GongF.HanY.QiuY.WangJ.LiuY.WeiY.XiaJ.a.YuT.ZhangX.ZhangL.Epidemiological and clinical characteristics of 99 cases of 2019 novel" exact="coronavirus pneumonia" post="in Wuhan, China: a descriptive studyLancet395202050751332007143 20WangY.WangY.ChenY.QinQ.Unique epidemiological and"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet395202050751332007143 20WangY.WangY.ChenY.QinQ.Unique epidemiological and"/>
  <result pre="20WangY.WangY.ChenY.QinQ.Unique epidemiological and clinical features of the emerging 2019 novel" exact="coronavirus pneumonia" post="(COVID-19) implicate special control measuresJ. Med. Virol.202010.1002/jmv.25748(Epub ahead of"/>
  <result pre="epidemiological and clinical features of the emerging 2019 novel coronavirus" exact="pneumonia" post="(COVID-19) implicate special control measuresJ. Med. Virol.202010.1002/jmv.25748(Epub ahead of"/>
  <result pre="in China: a systematic reviewJ. Med. Virol.92202047949010.1002/jmv.2570732052466 31ZhengY.-Y.MaY.-T.ZhangJ.-Y.XieX.COVID-19 and the" exact="cardiovascular" post="systemNat. Rev. Cardiol.202010.1038/s41569-020-0360-5(Epub ahead of print) 32FangL.KarakiulakisG.RothM.Are patients with"/>
  <result pre="cardiovascular systemNat. Rev. Cardiol.202010.1038/s41569-020-0360-5(Epub ahead of print) 32FangL.KarakiulakisG.RothM.Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
  <result pre="Rev. Cardiol.202010.1038/s41569-020-0360-5(Epub ahead of print) 32FangL.KarakiulakisG.RothM.Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir. Med.82020e2110.1016/S2213-2600(20)30116-832171062 33CaiH.Sex"/>
  <result pre="the solution?J. Nutr. Sci.62017e210.1017/jns.2016.4228620477 39ConzadeR.KoenigW.HeierM.SchneiderA.GrillE.PetersA.ThorandB.Prevalence and predictors of subclinical micronutrient" exact="deficiency" post="in German older adults: results from the population-based KORA-age"/>
  <result pre="control of the microbiota prevents obesityScience365201931631731346050 42KumpitschC.KoskinenK.SchöpfV.Moissl-EichingerC.The microbiome of the" exact="upper" post="respiratory tract in health and diseaseBMC Biol.1720198710.1186/s12915-019-0703-z31699101 43VlasovaA.N.TakanashiS.MiyazakiA.RajashekaraG.SaifL.J.How the"/>
  <result pre="of the microbiota prevents obesityScience365201931631731346050 42KumpitschC.KoskinenK.SchöpfV.Moissl-EichingerC.The microbiome of the upper" exact="respiratory" post="tract in health and diseaseBMC Biol.1720198710.1186/s12915-019-0703-z31699101 43VlasovaA.N.TakanashiS.MiyazakiA.RajashekaraG.SaifL.J.How the gut"/>
  <result pre="Biol.1720198710.1186/s12915-019-0703-z31699101 43VlasovaA.N.TakanashiS.MiyazakiA.RajashekaraG.SaifL.J.How the gut microbiome regulates host immune responses to" exact="viral" post="vaccinesCurr. Opin. Virol.372019162531163292 44HanadaS.PirzadehM.CarverK.Y.DengJ.C.Respiratory viral infection-induced microbiome alterations and"/>
  <result pre="regulates host immune responses to viral vaccinesCurr. Opin. Virol.372019162531163292 44HanadaS.PirzadehM.CarverK.Y.DengJ.C.Respiratory" exact="viral" post="infection-induced microbiome alterations and secondary bacterial pneumoniaFront. Immunol.92018264010.3389/fimmu.2018.0264030505304 45SamuelsonD.R.WelshD.A.ShellitoJ.E.Regulation"/>
  <result pre="viral vaccinesCurr. Opin. Virol.372019162531163292 44HanadaS.PirzadehM.CarverK.Y.DengJ.C.Respiratory viral infection-induced microbiome alterations and" exact="secondary" post="bacterial pneumoniaFront. Immunol.92018264010.3389/fimmu.2018.0264030505304 45SamuelsonD.R.WelshD.A.ShellitoJ.E.Regulation of lung immunity and host"/>
  <result pre="vaccinesCurr. Opin. Virol.372019162531163292 44HanadaS.PirzadehM.CarverK.Y.DengJ.C.Respiratory viral infection-induced microbiome alterations and secondary" exact="bacterial" post="pneumoniaFront. Immunol.92018264010.3389/fimmu.2018.0264030505304 45SamuelsonD.R.WelshD.A.ShellitoJ.E.Regulation of lung immunity and host defense"/>
  <result pre="defense by the intestinal microbiotaFront. Microbiol.62015108510.3389/fmicb.2015.0108526500629 46ZhouJ.WangY.ChangQ.MaP.HuY.CaoX.Type III interferons in" exact="viral infection" post="and antiviral immunityCell. Physiol. Biochem.51201817318530439714 47TeijaroJ.R.Type I interferons in"/>
  <result pre="by the intestinal microbiotaFront. Microbiol.62015108510.3389/fmicb.2015.0108526500629 46ZhouJ.WangY.ChangQ.MaP.HuY.CaoX.Type III interferons in viral" exact="infection" post="and antiviral immunityCell. Physiol. Biochem.51201817318530439714 47TeijaroJ.R.Type I interferons in"/>
  <result pre="infection and antiviral immunityCell. Physiol. Biochem.51201817318530439714 47TeijaroJ.R.Type I interferons in" exact="viral" post="control and immune regulationCurr. Opin. Virol.162016314026812607 48MuriraA.LamarreA.Type-I interferon responses:"/>
  <result pre="interferon responses: from friend to foe in the battle against" exact="chronic" post="viral infectionFront. Immunol.7201660910.3389/fimmu.2016.0060928066419 49VouloumanouE.K.MakrisG.C.KarageorgopoulosD.E.FalagasM.E.Probiotics for the prevention of respiratory"/>
  <result pre="responses: from friend to foe in the battle against chronic" exact="viral" post="infectionFront. Immunol.7201660910.3389/fimmu.2016.0060928066419 49VouloumanouE.K.MakrisG.C.KarageorgopoulosD.E.FalagasM.E.Probiotics for the prevention of respiratory tract"/>
  <result pre="against chronic viral infectionFront. Immunol.7201660910.3389/fimmu.2016.0060928066419 49VouloumanouE.K.MakrisG.C.KarageorgopoulosD.E.FalagasM.E.Probiotics for the prevention of" exact="respiratory" post="tract infections: a systematic reviewInt. J. Antimicrob. Agents342009197.e1197.e1010.1016/j.ijantimicag.2008.11.00519179052 50HoriT.KiyoshimaJ.ShidaK.YasuiH.Augmentation"/>
  <result pre="54TrompetteA.GollwitzerE.S.PattaroniC.Lopez-MejiaI.C.RivaE.PernotJ.UbagsN.FajasL.NicodL.P.MarslandB.J.Dietary fiber confers protection against flu by shaping Ly6c− patrolling" exact="monocyte" post="hematopoiesis and CD8+ T cell metabolismImmunity4820189921005.e810.1016/j.immuni.2018.04.02229768180 55KanauchiO.AndohA.AbuBakarS.YamamotoN.Probiotics and paraprobiotics"/>
  <result pre="hematopoiesis and CD8+ T cell metabolismImmunity4820189921005.e810.1016/j.immuni.2018.04.02229768180 55KanauchiO.AndohA.AbuBakarS.YamamotoN.Probiotics and paraprobiotics in" exact="viral" post="infection: clinical application and effects on the innate and"/>
  <result pre="viral infection: clinical application and effects on the innate and" exact="acquired" post="immune systemsCurr. Pharm. Des.24201871071710.2174/138161282466618011616341129345577 56EguchiK.FujitaniN.NakagawaH.MiyazakiT.Prevention of respiratory syncytial virus"/>
  <result pre="the innate and acquired immune systemsCurr. Pharm. Des.24201871071710.2174/138161282466618011616341129345577 56EguchiK.FujitaniN.NakagawaH.MiyazakiT.Prevention of" exact="respiratory" post="syncytial virus infection with probiotic lactic acid bacterium Lactobacillus"/>
  <result pre="and acquired immune systemsCurr. Pharm. Des.24201871071710.2174/138161282466618011616341129345577 56EguchiK.FujitaniN.NakagawaH.MiyazakiT.Prevention of respiratory syncytial" exact="virus infection" post="with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055Sci. Rep.92019481210.1038/s41598-019-39602-730886158"/>
  <result pre="acquired immune systemsCurr. Pharm. Des.24201871071710.2174/138161282466618011616341129345577 56EguchiK.FujitaniN.NakagawaH.MiyazakiT.Prevention of respiratory syncytial virus" exact="infection" post="with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055Sci. Rep.92019481210.1038/s41598-019-39602-730886158"/>
  <result pre="probiotic lactic acid bacterium Lactobacillus gasseri SBT2055Sci. Rep.92019481210.1038/s41598-019-39602-730886158 57LehtorantaL.PitkärantaA.KorpelaR.Probiotics in" exact="respiratory" post="virus infectionsEur. J. Clin. Microbiol. Infect. Dis.3320141289130224638909 58MagginiS.PierreA.CalderP.C.Immune function"/>
  <result pre="well-functioning immune system is an important factor to protect against" exact="viral" post="infectionsPreprints. Retrieved fromhttps://www.preprints.org/manuscript/202003.0199/v1(Accessed: 7 April 2020) 60KritasS.RonconiG.CaraffaA.GallengaC.RossR.ContiP.Mast cells contribute"/>
  <result pre="Homeost. Agents34202010.23812/20-Editorial-Kritas 61ContiP.RonconiG.CaraffaA.GallengaC.E.RossR.FrydasI.KritasS.K.Induction of pro-inflammatory cytokines (IL-1 and IL-6) and" exact="lung inflammation" post="by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategiesJ. Biol. Regul."/>
  <result pre="SARS-CoV-2): anti-inflammatory strategiesJ. Biol. Regul. Homeost. Agents34202010.23812/CONTI-E 62BergmanP.LindhA.U.Björkhem-BergmanL.LindhJ.D.Vitamin D and" exact="respiratory" post="tract infections: a systematic review and meta-analysis of randomized"/>
  <result pre="of randomized controlled trialsPLoS One82013e6583510.1371/journal.pone.0065835 63CharanJ.GoyalJ.P.SaxenaD.YadavP.Vitamin D for prevention of" exact="respiratory" post="tract infections: a systematic review and meta-analysisJ. Pharmacol. Pharmacother.3201230030323326099"/>
  <result pre="review and meta-analysisJ. Pharmacol. Pharmacother.3201230030323326099 64MartineauA.R.JolliffeD.A.HooperR.L.GreenbergL.AloiaJ.F.BergmanP.Dubnov-RazG.EspositoS.GanmaaD.GindeA.A.GoodallE.C.GrantC.C.GriffithsC.J.JanssensW.LaaksiI.Manaseki-HollandS.MaugerD.MurdochD.R.NealeR.ReesJ.R.SimpsonS.StelmachI.KumarG.T.UrashimaM.CamargoC.A.Vitamin D supplementation to prevent" exact="acute" post="respiratory tract infections: systematic review and meta-analysis of individual"/>
  <result pre="and meta-analysisJ. Pharmacol. Pharmacother.3201230030323326099 64MartineauA.R.JolliffeD.A.HooperR.L.GreenbergL.AloiaJ.F.BergmanP.Dubnov-RazG.EspositoS.GanmaaD.GindeA.A.GoodallE.C.GrantC.C.GriffithsC.J.JanssensW.LaaksiI.Manaseki-HollandS.MaugerD.MurdochD.R.NealeR.ReesJ.R.SimpsonS.StelmachI.KumarG.T.UrashimaM.CamargoC.A.Vitamin D supplementation to prevent acute" exact="respiratory" post="tract infections: systematic review and meta-analysis of individual participant"/>
  <result pre="of individual participant dataBMJ3562017i658310.1136/bmj.i658328202713 65MartineauA.R.JolliffeD.A.GreenbergL.AloiaJ.F.BergmanP.Dubnov-RazG.EspositoS.GanmaaD.GindeA.A.GoodallE.C.GrantC.C.JanssensW.JensenM.E.KerleyC.P.LaaksiI.Manaseki-HollandS.MaugerD.MurdochD.R.NealeR.ReesJ.R.SimpsonS.StelmachI.KumarG. TrilokUrashimaM.CamargoC.A.GriffithsC.J.HooperR.L.Vitamin D supplementation to prevent" exact="acute" post="respiratory infections: individual participant data meta-analysisHealth Technol. Assess. (Winchester,"/>
  <result pre="individual participant dataBMJ3562017i658310.1136/bmj.i658328202713 65MartineauA.R.JolliffeD.A.GreenbergL.AloiaJ.F.BergmanP.Dubnov-RazG.EspositoS.GanmaaD.GindeA.A.GoodallE.C.GrantC.C.JanssensW.JensenM.E.KerleyC.P.LaaksiI.Manaseki-HollandS.MaugerD.MurdochD.R.NealeR.ReesJ.R.SimpsonS.StelmachI.KumarG. TrilokUrashimaM.CamargoC.A.GriffithsC.J.HooperR.L.Vitamin D supplementation to prevent acute" exact="respiratory" post="infections: individual participant data meta-analysisHealth Technol. Assess. (Winchester, England)232019144"/>
  <result pre="Technol. Assess. (Winchester, England)232019144 66Teymoori-RadM.ShokriF.SalimiV.MarashiS.M.The interplay between vitamin D and" exact="viral" post="infectionsRev. Med. Virol.292019e203210.1002/rmv.2032 67GrantW.B.LahoreH.McDonnellS.L.BaggerlyC.A.FrenchC.B.AlianoJ.L.BhattoaH.P.Evidence that vitamin D supplementation could"/>
  <result pre="vitamin D supplementation could reduce risk of influenza and COVID-19" exact="infections" post="and deathsNutrients12202010.3390/nu12040988 68NairR.MaseehA.Vitamin D: the &quot;sunshine&quot; vitaminJ. Pharmacol. Pharmacother.3201211812610.4103/0976-500X.9550622629085"/>
  <result pre="risks for women in long-term care: high prevalence of calcaneal" exact="osteoporosis" post="and hypovitaminosis DPharmacotherapy23200370271010.1592/phco.23.6.702.3218212820811 70KennelK.A.DrakeM.T.HurleyD.L.Vitamin D deficiency in adults: when"/>
  <result pre="high prevalence of calcaneal osteoporosis and hypovitaminosis DPharmacotherapy23200370271010.1592/phco.23.6.702.3218212820811 70KennelK.A.DrakeM.T.HurleyD.L.Vitamin D" exact="deficiency" post="in adults: when to test and how to treatMayo"/>
  <result pre="71HolickM.F.Sunlight and vitamin D for bone health and prevention of" exact="autoimmune" post="diseases, cancers, and cardiovascular diseaseAm. J. Clin. Nutr.8020041678S1688S15585788 72NonneckeB.McGillJ.RidpathJ.SaccoR.LippolisJ.ReinhardtT.Acute"/>
  <result pre="for bone health and prevention of autoimmune diseases, cancers, and" exact="cardiovascular" post="diseaseAm. J. Clin. Nutr.8020041678S1688S15585788 72NonneckeB.McGillJ.RidpathJ.SaccoR.LippolisJ.ReinhardtT.Acute phase response elicited by"/>
  <result pre="J. Clin. Nutr.8020041678S1688S15585788 72NonneckeB.McGillJ.RidpathJ.SaccoR.LippolisJ.ReinhardtT.Acute phase response elicited by experimental bovine" exact="diarrhea" post="virus (BVDV) infection is associated with decreased vitamin D"/>
  <result pre="72NonneckeB.McGillJ.RidpathJ.SaccoR.LippolisJ.ReinhardtT.Acute phase response elicited by experimental bovine diarrhea virus (BVDV)" exact="infection" post="is associated with decreased vitamin D and E status"/>
  <result pre="preruminant calvesJ. Dairy Sci.9720145566557925022687 73GreillerC.L.MartineauA.R.Modulation of the Immune response to" exact="respiratory" post="viruses by vitamin DNutrients720154240427010.3390/nu706424026035247 74ScienceM.MaguireJ.L.RussellM.L.SmiejaM.WalterS.D.LoebM.Low serum 25-hydroxyvitamin D level"/>
  <result pre="vitamin DNutrients720154240427010.3390/nu706424026035247 74ScienceM.MaguireJ.L.RussellM.L.SmiejaM.WalterS.D.LoebM.Low serum 25-hydroxyvitamin D level and risk of" exact="upper respiratory tract infection" post="in children and adolescentsClin Infect. Dis.57201339239710.1093/cid/cit28923677871 75WimalawansaS.J.Global epidemic of"/>
  <result pre="DNutrients720154240427010.3390/nu706424026035247 74ScienceM.MaguireJ.L.RussellM.L.SmiejaM.WalterS.D.LoebM.Low serum 25-hydroxyvitamin D level and risk of upper" exact="respiratory" post="tract infection in children and adolescentsClin Infect. Dis.57201339239710.1093/cid/cit28923677871 75WimalawansaS.J.Global"/>
  <result pre="serum 25-hydroxyvitamin D level and risk of upper respiratory tract" exact="infection" post="in children and adolescentsClin Infect. Dis.57201339239710.1093/cid/cit28923677871 75WimalawansaS.J.Global epidemic of"/>
  <result pre="J. Biomed. Pharm. Sci.72020432438https://www.ejbps.com/ejbps/abstract_id/6656 76SembaR.D.Vitamin A and immunity to viral," exact="bacterial" post="and protozoan infectionsProc. Nutr. Soc.58199971972710.1017/s002966519900094410604208 77McGillJ.L.KellyS.M.Guerra-MaupomeM.WinkleyE.HenningsonJ.NarasimhanB.SaccoR.E.Vitamin A deficiency impairs"/>
  <result pre="to viral, bacterial and protozoan infectionsProc. Nutr. Soc.58199971972710.1017/s002966519900094410604208 77McGillJ.L.KellyS.M.Guerra-MaupomeM.WinkleyE.HenningsonJ.NarasimhanB.SaccoR.E.Vitamin A" exact="deficiency" post="impairs the immune response to intranasal vaccination and RSV"/>
  <result pre="deficiency impairs the immune response to intranasal vaccination and RSV" exact="infection" post="in neonatal calvesSci. Rep.920191515710.1038/s41598-019-51684-x31641172 78PatelN.PenkertR.R.JonesB.G.SealyR.E.SurmanS.L.SunY.TangL.DeBeauchampJ.WebbA.RichardsonJ.HeineR.DallasR.H.RossA.C.WebbyR.HurwitzJ.L.Baseline serum vitamin A and"/>
  <result pre="the immune response to intranasal vaccination and RSV infection in" exact="neonatal" post="calvesSci. Rep.920191515710.1038/s41598-019-51684-x31641172 78PatelN.PenkertR.R.JonesB.G.SealyR.E.SurmanS.L.SunY.TangL.DeBeauchampJ.WebbA.RichardsonJ.HeineR.DallasR.H.RossA.C.WebbyR.HurwitzJ.L.Baseline serum vitamin A and D levels"/>
  <result pre="bovine coronavirus vaccineAm. J. Vet. Res.7420131353136224066921 80KańtochM.LitwińskaB.SzkodaM.SiennickaJ.Importance of vitamin A" exact="deficiency" post="in pathology and immunology of viral infectionsRocz. Panstw. Zakl."/>
  <result pre="80KańtochM.LitwińskaB.SzkodaM.SiennickaJ.Importance of vitamin A deficiency in pathology and immunology of" exact="viral" post="infectionsRocz. Panstw. Zakl. Hig.532002385392https://www.ncbi.nlm.nih.gov/pubmed/1266466612664666 81HessA.F.Diet, nutrition and infectionN. Engl."/>
  <result pre="88van DrielM.L.BellerE.M.ThielemansE.DeckxL.Price-HaywoodE.ClarkJ.De SutterA.I.M.Oral vitamin C supplements to prevent and treat" exact="acute" post="upper respiratory tract infectionsCochrane Database Syst. Rev.201932019CD01329210.1002/14651858.CD013292 89HemiläH.Vitamin C"/>
  <result pre="DrielM.L.BellerE.M.ThielemansE.DeckxL.Price-HaywoodE.ClarkJ.De SutterA.I.M.Oral vitamin C supplements to prevent and treat acute" exact="upper" post="respiratory tract infectionsCochrane Database Syst. Rev.201932019CD01329210.1002/14651858.CD013292 89HemiläH.Vitamin C supplementation"/>
  <result pre="SutterA.I.M.Oral vitamin C supplements to prevent and treat acute upper" exact="respiratory" post="tract infectionsCochrane Database Syst. Rev.201932019CD01329210.1002/14651858.CD013292 89HemiläH.Vitamin C supplementation and"/>
  <result pre="vitamin C in preventing and relieving the symptoms of virus-induced" exact="respiratory" post="infectionsJ. Manipulative Physiol. Ther.22199953053310543583 93MagginiS.BeveridgeS.SuterM.A combination of high-dose vitamin"/>
  <result pre="for the common coldJ. Int. Med. Res.402012284222429343 94GuillinO.M.VindryC.OhlmannT.ChavatteL.Selenium, selenoproteins and" exact="viral" post="infectionNutrients112019210110.3390/nu11092101 95BeckM.A.NelsonH.K.ShiQ.Van DaelP.SchiffrinE.J.BlumS.BarclayD.LevanderO.A.Selenium deficiency increases the pathology of an"/>
  <result pre="Int. Med. Res.402012284222429343 94GuillinO.M.VindryC.OhlmannT.ChavatteL.Selenium, selenoproteins and viral infectionNutrients112019210110.3390/nu11092101 95BeckM.A.NelsonH.K.ShiQ.Van DaelP.SchiffrinE.J.BlumS.BarclayD.LevanderO.A.Selenium" exact="deficiency" post="increases the pathology of an influenza virus infectionFASEB J.1520011481148310.1096/fj.00-0721fje11387264"/>
  <result pre="in selection of identical virulent isolatesNat. Med.1199543343610.1038/nm0595-4337585090 98HarthillM.Review: micronutrient selenium" exact="deficiency" post="influences evolution of some viral infectious diseasesBiol. Trace Elem."/>
  <result pre="isolatesNat. Med.1199543343610.1038/nm0595-4337585090 98HarthillM.Review: micronutrient selenium deficiency influences evolution of some" exact="viral" post="infectious diseasesBiol. Trace Elem. Res.14320111325133621318622 99RaymanM.P.Selenium and human healthLancet37920121256126822381456"/>
  <result pre="Med.1199543343610.1038/nm0595-4337585090 98HarthillM.Review: micronutrient selenium deficiency influences evolution of some viral" exact="infectious" post="diseasesBiol. Trace Elem. Res.14320111325133621318622 99RaymanM.P.Selenium and human healthLancet37920121256126822381456 100ShojadoostB.KulkarniR.R.YitbarekA.LaursenA.Taha-AbdelazizK.AlkieT.N.BarjestehN.Quinteiro-FilhoW.M.SmithT.K.SharifS.Dietary"/>
  <result pre="supplementation enhances antiviral immunity in chickens challenged with low pathogenic" exact="avian influenza" post="virus subtype H9N2Vet. Immunol. Immunopathol.2072019626830593352 101BeckM.A.LevanderO.A.HandyJ.Selenium deficiency and viral"/>
  <result pre="low pathogenic avian influenza virus subtype H9N2Vet. Immunol. Immunopathol.2072019626830593352 101BeckM.A.LevanderO.A.HandyJ.Selenium" exact="deficiency" post="and viral infectionJ. Nutr.13320031463S1467S10.1093/jn/133.5.1463S12730444 102RazzaqueM.COVID-19 pandemic: Can maintaining optimal"/>
  <result pre="avian influenza virus subtype H9N2Vet. Immunol. Immunopathol.2072019626830593352 101BeckM.A.LevanderO.A.HandyJ.Selenium deficiency and" exact="viral" post="infectionJ. Nutr.13320031463S1467S10.1093/jn/133.5.1463S12730444 102RazzaqueM.COVID-19 pandemic: Can maintaining optimal zinc balance"/>
  <result pre="meta-analysis of randomized controlled trialsCmaj1842012E551E56110.1503/cmaj.11199022566526 107SaigalP.HanekomD.Does zinc improve symptoms of" exact="viral" post="upper respiratory tract infection?Evid. Based Pract.2320203739 108AwotiwonA.A.OduwoleO.SinhaA.OkwunduC.I.Zinc supplementation for"/>
  <result pre="of randomized controlled trialsCmaj1842012E551E56110.1503/cmaj.11199022566526 107SaigalP.HanekomD.Does zinc improve symptoms of viral" exact="upper" post="respiratory tract infection?Evid. Based Pract.2320203739 108AwotiwonA.A.OduwoleO.SinhaA.OkwunduC.I.Zinc supplementation for the"/>
  <result pre="randomized controlled trialsCmaj1842012E551E56110.1503/cmaj.11199022566526 107SaigalP.HanekomD.Does zinc improve symptoms of viral upper" exact="respiratory" post="tract infection?Evid. Based Pract.2320203739 108AwotiwonA.A.OduwoleO.SinhaA.OkwunduC.I.Zinc supplementation for the treatment"/>
  <result pre="tract infection?Evid. Based Pract.2320203739 108AwotiwonA.A.OduwoleO.SinhaA.OkwunduC.I.Zinc supplementation for the treatment of" exact="measles" post="in childrenCochrane Database Syst. Rev.62017CD01117710.1002/14651858.CD011177.pub328631310 109ReadS.A.ParnellG.BoothD.DouglasM.W.GeorgeJ.AhlenstielG.The antiviral role of"/>
  <result pre="Syst. Rev.62017CD01117710.1002/14651858.CD011177.pub328631310 109ReadS.A.ParnellG.BoothD.DouglasM.W.GeorgeJ.AhlenstielG.The antiviral role of zinc and metallothioneins in" exact="hepatitis" post="C infectionJ. Viral Hepat.25201849150129239069 110MatsuokaS.MatsumuraH.NakamuraH.OshiroS.ArakawaY.HayashiJ.SekineN.NireiK.YamagamiH.OgawaM.NakajimaN.AmakiS.TanakaN.MoriyamaM.Zinc supplementation improves the outcome"/>
  <result pre="antiviral role of zinc and metallothioneins in hepatitis C infectionJ." exact="Viral" post="Hepat.25201849150129239069 110MatsuokaS.MatsumuraH.NakamuraH.OshiroS.ArakawaY.HayashiJ.SekineN.NireiK.YamagamiH.OgawaM.NakajimaN.AmakiS.TanakaN.MoriyamaM.Zinc supplementation improves the outcome of chronic hepatitis"/>
  <result pre="C infectionJ. Viral Hepat.25201849150129239069 110MatsuokaS.MatsumuraH.NakamuraH.OshiroS.ArakawaY.HayashiJ.SekineN.NireiK.YamagamiH.OgawaM.NakajimaN.AmakiS.TanakaN.MoriyamaM.Zinc supplementation improves the outcome of" exact="chronic hepatitis" post="C and liver cirrhosisJ. Clin. Biochem. Nutr.45200929230310.3164/jcbn.jcbn08-24619902019 111WangY.ZhuL.Q.Pharmaceutical care"/>
  <result pre="infectionJ. Viral Hepat.25201849150129239069 110MatsuokaS.MatsumuraH.NakamuraH.OshiroS.ArakawaY.HayashiJ.SekineN.NireiK.YamagamiH.OgawaM.NakajimaN.AmakiS.TanakaN.MoriyamaM.Zinc supplementation improves the outcome of chronic" exact="hepatitis" post="C and liver cirrhosisJ. Clin. Biochem. Nutr.45200929230310.3164/jcbn.jcbn08-24619902019 111WangY.ZhuL.Q.Pharmaceutical care"/>
  <result pre="Nutr.45200929230310.3164/jcbn.jcbn08-24619902019 111WangY.ZhuL.Q.Pharmaceutical care recommendations for antiviral treatments in children with" exact="coronavirus disease" post="2019World J. Pediatr.202010.1007/s12519-020-00353-5(Epub ahead of print) 112HarrisonC.Coronavirus puts drug"/>
  <result pre="111WangY.ZhuL.Q.Pharmaceutical care recommendations for antiviral treatments in children with coronavirus" exact="disease" post="2019World J. Pediatr.202010.1007/s12519-020-00353-5(Epub ahead of print) 112HarrisonC.Coronavirus puts drug"/>
  <result pre="trackNat. Biotechnol.202010.1038/d41587-020-00003-1(Epub ahead of print) 113KonoM.TatsumiK.ImaiA.M.SaitoK.KuriyamaT.ShirasawaH.Inhibition of human coronavirus 229E" exact="infection" post="in human epithelial lung cells (L132) by chloroquine: involvement"/>
  <result pre="of print) 113KonoM.TatsumiK.ImaiA.M.SaitoK.KuriyamaT.ShirasawaH.Inhibition of human coronavirus 229E infection in human" exact="epithelial" post="lung cells (L132) by chloroquine: involvement of p38 MAPK"/>
  <result pre="of monovalent human rotavirus vaccine against admission to hospital for" exact="acute" post="rotavirus diarrhoea in south African children: a case-control studyLancet"/>
  <result pre="against admission to hospital for acute rotavirus diarrhoea in south" exact="African" post="children: a case-control studyLancet Infect. Dis.1420141096110425303843 117HoffmannM.Kleine-WeberH.SchroederS.KrügerN.HerrlerT.ErichsenS.SchiergensT.S.HerrlerG.WuN.-H.NitscheA.MüllerM.A.DrostenC.PöhlmannS.SARS-CoV-2 cell entry"/>
  <result pre="by computational methodsActa Pharm. Sin. B202010.1016/j.apsb.2020.02.008(Epub ahead of print) 121AgostiniM.L.AndresE.L.SimsA.C.GrahamR.L.SheahanT.P.LuX.SmithE.C.CaseJ.B.FengJ.Y.JordanR.RayA.S.CihlarT.SiegelD.MackmanR.L.ClarkeM.O.BaricR.S.DenisonM.R.Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
  <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleasemBio9201810.1128/mBio.00221-18 122WarrenT.K.JordanR.LoM.K.RayA.S.MackmanR.L.SolovevaV.SiegelD.PerronM.BannisterR.HuiH.C.LarsonN.StrickleyR.WellsJ.StuthmanK.S.Van TongerenS.A.GarzaN.L.DonnellyG.ShurtleffA.C.RettererC.J.GharaibehD.ZamaniR.KennyT.EatonB.P.GrimesE.WelchL.S.GombaL.WilhelmsenC.L.NicholsD.K.NussJ.E.NagleE.R.KugelmanJ.R.PalaciosG.DoerfflerE.NevilleS.CarraE.ClarkeM.O.ZhangL.LewW.RossB.WangQ.ChunK.WolfeL.BabusisD.ParkY.StrayK.M.TranchevaI.FengJ.Y.BarauskasO.XuY.WongP.BraunM.R.FlintM.McMullanL.K.ChenS.-S.FearnsR.SwaminathanS.MayersD.L.SpiropoulouC.F.LeeW.A.NicholS.T.CihlarT.BavariS.Therapeutic efficacy of"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov.620201610.1038/s41421-020-0156-032194981 127AmirianE.S.LevyJ.K.Current knowledge about the antivirals remdesivir"/>
  <result pre="131FurutaY.TakahashiK.ShirakiK.SakamotoK.SmeeD.F.BarnardD.L.GowenB.B.JulanderJ.G.MorreyJ.D.T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA" exact="viral" post="infectionsAntivir. Res.8220099510219428599 132De ClercqE.New nucleoside analogues for the treatment"/>
  <result pre="reviewTher. Clin. Risk Manag.420081023103310.2147/tcrm.s328519209283 138JiangF.DengL.ZhangL.CaiY.CheungC.W.XiaZ.Review of the clinical characteristics of" exact="coronavirus disease" post="2019 (COVID-19)J. Gen. Intern. Med.202010.1007/s11606-020-05762-w(Epub ahead of print) 139CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.LiX.XiaJ.ChenN.XiangJ.YuT.BaiT.XieX.ZhangL.LiC.YuanY.ChenH.LiH.HuangH.TuS.GongF.LiuY.WeiY.DongC.ZhouF.GuX.XuJ.LiuZ.ZhangY.LiH.ShangL.WangK.LiK.ZhouX.DongX.QuZ.LuS.HuX.RuanS.LuoS.WuJ.PengL.ChengF.PanL.ZouJ.JiaC.WangJ.LiuX.WangS.WuX.GeQ.HeJ.ZhanH.QiuF.GuoL.HuangC.JakiT.HaydenF.G.HorbyP.W.ZhangD.WangC.A"/>
  <result pre="Clin. Risk Manag.420081023103310.2147/tcrm.s328519209283 138JiangF.DengL.ZhangL.CaiY.CheungC.W.XiaZ.Review of the clinical characteristics of coronavirus" exact="disease" post="2019 (COVID-19)J. Gen. Intern. Med.202010.1007/s11606-020-05762-w(Epub ahead of print) 139CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.LiX.XiaJ.ChenN.XiangJ.YuT.BaiT.XieX.ZhangL.LiC.YuanY.ChenH.LiH.HuangH.TuS.GongF.LiuY.WeiY.DongC.ZhouF.GuX.XuJ.LiuZ.ZhangY.LiH.ShangL.WangK.LiK.ZhouX.DongX.QuZ.LuS.HuX.RuanS.LuoS.WuJ.PengL.ChengF.PanL.ZouJ.JiaC.WangJ.LiuX.WangS.WuX.GeQ.HeJ.ZhanH.QiuF.GuoL.HuangC.JakiT.HaydenF.G.HorbyP.W.ZhangD.WangC.A"/>
  <result pre="141KimU.J.WonE.-J.KeeS.-J.JungS.-I.JangH.-C.Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East" exact="respiratory" post="syndromeAntivir. Ther.21201645545910.3851/IMP300226492219 142ArabiY.M.AsiriA.Y.AssiriA.M.JokhdarH.A. AzizAlothmanA.BalkhyH.H.AlJohaniS.Al HarbiS.KojanS.Al JeraisyM.DeebA.M.MemishZ.A.GhazalS.Al FarajS.Al-HameedF.AlSaediA.MandourahY.Al MekhlafiG.A.SherbeeniN.M.ElzeinF.E.AlmotairiA.Al BshabsheA.KharabaA.JoseJ.Al"/>
  <result pre="BshabsheA.KharabaA.JoseJ.Al HarthyA.Al SulaimanM.MadyA.FowlerR.A.HaydenF.G.Al-DawoodA.AbdelzaherM.BajhmomW.HusseinM.A.the Saudi Critical Care TrialsTreatment of Middle East" exact="respiratory" post="syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE"/>
  <result pre="HarthyA.Al SulaimanM.MadyA.FowlerR.A.HaydenF.G.Al-DawoodA.AbdelzaherM.BajhmomW.HusseinM.A.the Saudi Critical Care TrialsTreatment of Middle East respiratory" exact="syndrome" post="with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial):"/>
  <result pre="infection: a systematic reviewAIDS Res. Treat2017234561710.1155/2017/234561729082041 144DongL.HuS.GaoJ.Discovering drugs to treat" exact="coronavirus disease" post="2019 (COVID-19)Drug Discov. Ther.142020586032147628 145SeoJ.-Y.YanevaR.CresswellP.Viperin: a multifunctional, interferon-inducible protein"/>
  <result pre="a systematic reviewAIDS Res. Treat2017234561710.1155/2017/234561729082041 144DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discov. Ther.142020586032147628 145SeoJ.-Y.YanevaR.CresswellP.Viperin: a multifunctional, interferon-inducible protein"/>
  <result pre="and perspectiveInt. J. Biol. Sci.1620201708171732226288 150NeedleD.LountosG.T.WaughD.S.Structures of the Middle East" exact="respiratory" post="syndrome coronavirus 3C-like protease reveal insights into substrate specificityActa"/>
  <result pre="perspectiveInt. J. Biol. Sci.1620201708171732226288 150NeedleD.LountosG.T.WaughD.S.Structures of the Middle East respiratory" exact="syndrome" post="coronavirus 3C-like protease reveal insights into substrate specificityActa Crystallogr."/>
  <result pre="152ChenL.GuiC.LuoX.YangQ.GüntherS.ScandellaE.DrostenC.BaiD.HeX.LudewigB.Cinanserin is an inhibitor of the 3C-like proteinase of severe" exact="acute" post="respiratory syndrome coronavirus and strongly reduces virus replication in"/>
  <result pre="is an inhibitor of the 3C-like proteinase of severe acute" exact="respiratory" post="syndrome coronavirus and strongly reduces virus replication in vitroJ."/>
  <result pre="an inhibitor of the 3C-like proteinase of severe acute respiratory" exact="syndrome" post="coronavirus and strongly reduces virus replication in vitroJ. Virol.7920057095710310.1128/JVI.79.11.7095-7103.200515890949"/>
  <result pre="160CasadevallA.ScharffM.D.Return to the past: the case for antibody-based therapies in" exact="infectious" post="diseasesClin. Infect. Dis.2119951501617578724 161CasadevallA.DadachovaE.PirofskiL.A.Passive antibody therapy for infectious diseasesNat."/>
  <result pre="therapies in infectious diseasesClin. Infect. Dis.2119951501617578724 161CasadevallA.DadachovaE.PirofskiL.A.Passive antibody therapy for" exact="infectious" post="diseasesNat. Rev. Microbiol.2200469570310.1038/nrmicro97415372080 162GolubE.S.Monoclonal antibodiesBrennerS.MillerJ.H.Encyclopedia of Genetics2001Academic PressNew York12351237"/>
  <result pre="of investigational vaccine for COVID-19 begins: Study enrolling Seattle-based healthy" exact="adult" post="volunteershttps://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins(Accessed: 7 April 2020)"/>
 </snippets>
</snippetsTree>
